Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria
Abstract Objective To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. Patients and Methods We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptom...
Gespeichert in:
Veröffentlicht in: | Mayo Clinic proceedings 2013-02, Vol.88 (2), p.129-138 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 138 |
---|---|
container_issue | 2 |
container_start_page | 129 |
container_title | Mayo Clinic proceedings |
container_volume | 88 |
creator | Loo, Ronald K., MD Lieberman, Stephen F., MD Slezak, Jeff M., MS Landa, Howard M., MD Mariani, Albert J., MD Nicolaisen, Gary, MD Aspera, Ann M., MD Jacobsen, Steven J., MD, PhD |
description | Abstract Objective To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. Patients and Methods We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptomatic microscopic hematuria during a 2-year period in an integrated care organization in 3 regions along the West Coast of the United States. A test cohort and validation cohort of patients with hematuria evaluations between January 9, 2009, and August 15, 2011, were identified. Patients were followed passively through their electronic health records for a diagnosis of urothelial or renal cancer. The degree of microscopic hematuria, history of gross hematuria, smoking history, age, race, imaging findings, and cystoscopy findings were evaluated as risk factors for malignant tumors. Results The test cohort consisted of 2630 patients, of whom 55 (2.1%) had a neoplasm detected and 50 (1.9%) had a pathologically confirmed urinary tract cancer. Age of 50 years or older and a recent diagnosis of gross hematuria were the strongest predictors of cancer. Male sex was also predictive of cancer, whereas smoking history and 25 or more red blood cells per high-power field on a recent urinalysis were not statistically significant. A Hematuria Risk Index developed from these factors had an area under the receiver operating characteristic curve of 0.809. In the validation cohort of 1784 patients, the Hematuria Risk Index performed comparably (area under the curve = 0.829). Overall, 32% of the population was identified as low risk and 0.2% had a cancer detected; 14% of the population was identified as high risk, of whom 11.1% had a cancer found. Conclusion These results suggest that a considerable proportion of patients could avoid extensive evaluations with the use of the Hematuria Risk Index. |
doi_str_mv | 10.1016/j.mayocp.2012.10.004 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1284286288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A320735270</galeid><els_id>S0025619612009901</els_id><sourcerecordid>A320735270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-3fabb9f545684c31bd9cb0a98f8f9a6144357df79f62c9c9c9f124707f79401c3</originalsourceid><addsrcrecordid>eNqFUl1rFDEUDaLYdfUfiAQE8WXHfM1HXoSlqBVaFLvFx5DJJLvZziTTJCPsvzfD1K--yH1IOJxz7-WcC8BLjAqMcPXuWAzy5NVYEIRJhgqE2COwwpyRTVmy6jFYIUTKTYV5dQaexXhECNWcs6fgjFCKCa34CpjrFGSy5mTdHn6z8RZ6A2-CdTKc4C5IleCV7O3eSZfgbhp8iNA6-DVrtEsRfrfpALfxNIzJDxlU8Mqq4KPyY_5f6IxNwcrn4ImRfdQv7t81uPn4YXd-sbn88unz-fZyo0pcpg01sm25KVlZNUxR3HZctUjyxjSGywozRsu6MzU3FVF8LoMJq1GdIYawomvwduk7Bn836ZjEYKPSfS-d9lMUmDSMNBVpmkx9_YB69FNwebuZVXPCaR63BsXC2steC-uMz36pXJ0erPJOG5vxLSWopiWpURa8-Utw0LJPh-j7KVnv4r9EthBnu2LQRozBDtl2gZGYExZHsSQs5oRnNCecZa_u157aQXe_Rb8izYT3C0Fnn39YHURUOSulOxu0SqLz9n8THjZQvXVWyf5Wn3T845KIRCBxPV_ZfGSYIMQ5wvQnD7zMmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1287929344</pqid></control><display><type>article</type><title>Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Loo, Ronald K., MD ; Lieberman, Stephen F., MD ; Slezak, Jeff M., MS ; Landa, Howard M., MD ; Mariani, Albert J., MD ; Nicolaisen, Gary, MD ; Aspera, Ann M., MD ; Jacobsen, Steven J., MD, PhD</creator><creatorcontrib>Loo, Ronald K., MD ; Lieberman, Stephen F., MD ; Slezak, Jeff M., MS ; Landa, Howard M., MD ; Mariani, Albert J., MD ; Nicolaisen, Gary, MD ; Aspera, Ann M., MD ; Jacobsen, Steven J., MD, PhD</creatorcontrib><description>Abstract Objective To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. Patients and Methods We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptomatic microscopic hematuria during a 2-year period in an integrated care organization in 3 regions along the West Coast of the United States. A test cohort and validation cohort of patients with hematuria evaluations between January 9, 2009, and August 15, 2011, were identified. Patients were followed passively through their electronic health records for a diagnosis of urothelial or renal cancer. The degree of microscopic hematuria, history of gross hematuria, smoking history, age, race, imaging findings, and cystoscopy findings were evaluated as risk factors for malignant tumors. Results The test cohort consisted of 2630 patients, of whom 55 (2.1%) had a neoplasm detected and 50 (1.9%) had a pathologically confirmed urinary tract cancer. Age of 50 years or older and a recent diagnosis of gross hematuria were the strongest predictors of cancer. Male sex was also predictive of cancer, whereas smoking history and 25 or more red blood cells per high-power field on a recent urinalysis were not statistically significant. A Hematuria Risk Index developed from these factors had an area under the receiver operating characteristic curve of 0.809. In the validation cohort of 1784 patients, the Hematuria Risk Index performed comparably (area under the curve = 0.829). Overall, 32% of the population was identified as low risk and 0.2% had a cancer detected; 14% of the population was identified as high risk, of whom 11.1% had a cancer found. Conclusion These results suggest that a considerable proportion of patients could avoid extensive evaluations with the use of the Hematuria Risk Index.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2012.10.004</identifier><identifier>PMID: 23312369</identifier><identifier>CODEN: MACPAJ</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Age Distribution ; Aged ; Aged, 80 and over ; Asymptomatic Diseases - epidemiology ; California - epidemiology ; Causality ; Cohort Studies ; Comorbidity ; Complications and side effects ; Early Diagnosis ; Female ; Hematuria ; Hematuria - diagnosis ; Hematuria - epidemiology ; Humans ; Internal Medicine ; Male ; Middle Aged ; Northwestern United States - epidemiology ; Predictive Value of Tests ; Prevention ; Prospective Studies ; Risk Factors ; ROC Curve ; Sex Distribution ; Sex Factors ; United States ; Unnecessary Procedures ; Urinary tract cancer ; Urologic Neoplasms - diagnosis ; Urologic Neoplasms - epidemiology ; Validation Studies as Topic</subject><ispartof>Mayo Clinic proceedings, 2013-02, Vol.88 (2), p.129-138</ispartof><rights>Mayo Foundation for Medical Education and Research</rights><rights>2013 Mayo Foundation for Medical Education and Research</rights><rights>Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</rights><rights>COPYRIGHT 2013 Elsevier, Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Feb 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-3fabb9f545684c31bd9cb0a98f8f9a6144357df79f62c9c9c9f124707f79401c3</citedby><cites>FETCH-LOGICAL-c515t-3fabb9f545684c31bd9cb0a98f8f9a6144357df79f62c9c9c9f124707f79401c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1287929344?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23312369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loo, Ronald K., MD</creatorcontrib><creatorcontrib>Lieberman, Stephen F., MD</creatorcontrib><creatorcontrib>Slezak, Jeff M., MS</creatorcontrib><creatorcontrib>Landa, Howard M., MD</creatorcontrib><creatorcontrib>Mariani, Albert J., MD</creatorcontrib><creatorcontrib>Nicolaisen, Gary, MD</creatorcontrib><creatorcontrib>Aspera, Ann M., MD</creatorcontrib><creatorcontrib>Jacobsen, Steven J., MD, PhD</creatorcontrib><title>Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>Abstract Objective To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. Patients and Methods We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptomatic microscopic hematuria during a 2-year period in an integrated care organization in 3 regions along the West Coast of the United States. A test cohort and validation cohort of patients with hematuria evaluations between January 9, 2009, and August 15, 2011, were identified. Patients were followed passively through their electronic health records for a diagnosis of urothelial or renal cancer. The degree of microscopic hematuria, history of gross hematuria, smoking history, age, race, imaging findings, and cystoscopy findings were evaluated as risk factors for malignant tumors. Results The test cohort consisted of 2630 patients, of whom 55 (2.1%) had a neoplasm detected and 50 (1.9%) had a pathologically confirmed urinary tract cancer. Age of 50 years or older and a recent diagnosis of gross hematuria were the strongest predictors of cancer. Male sex was also predictive of cancer, whereas smoking history and 25 or more red blood cells per high-power field on a recent urinalysis were not statistically significant. A Hematuria Risk Index developed from these factors had an area under the receiver operating characteristic curve of 0.809. In the validation cohort of 1784 patients, the Hematuria Risk Index performed comparably (area under the curve = 0.829). Overall, 32% of the population was identified as low risk and 0.2% had a cancer detected; 14% of the population was identified as high risk, of whom 11.1% had a cancer found. Conclusion These results suggest that a considerable proportion of patients could avoid extensive evaluations with the use of the Hematuria Risk Index.</description><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asymptomatic Diseases - epidemiology</subject><subject>California - epidemiology</subject><subject>Causality</subject><subject>Cohort Studies</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Early Diagnosis</subject><subject>Female</subject><subject>Hematuria</subject><subject>Hematuria - diagnosis</subject><subject>Hematuria - epidemiology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Northwestern United States - epidemiology</subject><subject>Predictive Value of Tests</subject><subject>Prevention</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><subject>Sex Distribution</subject><subject>Sex Factors</subject><subject>United States</subject><subject>Unnecessary Procedures</subject><subject>Urinary tract cancer</subject><subject>Urologic Neoplasms - diagnosis</subject><subject>Urologic Neoplasms - epidemiology</subject><subject>Validation Studies as Topic</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFUl1rFDEUDaLYdfUfiAQE8WXHfM1HXoSlqBVaFLvFx5DJJLvZziTTJCPsvzfD1K--yH1IOJxz7-WcC8BLjAqMcPXuWAzy5NVYEIRJhgqE2COwwpyRTVmy6jFYIUTKTYV5dQaexXhECNWcs6fgjFCKCa34CpjrFGSy5mTdHn6z8RZ6A2-CdTKc4C5IleCV7O3eSZfgbhp8iNA6-DVrtEsRfrfpALfxNIzJDxlU8Mqq4KPyY_5f6IxNwcrn4ImRfdQv7t81uPn4YXd-sbn88unz-fZyo0pcpg01sm25KVlZNUxR3HZctUjyxjSGywozRsu6MzU3FVF8LoMJq1GdIYawomvwduk7Bn836ZjEYKPSfS-d9lMUmDSMNBVpmkx9_YB69FNwebuZVXPCaR63BsXC2steC-uMz36pXJ0erPJOG5vxLSWopiWpURa8-Utw0LJPh-j7KVnv4r9EthBnu2LQRozBDtl2gZGYExZHsSQs5oRnNCecZa_u157aQXe_Rb8izYT3C0Fnn39YHURUOSulOxu0SqLz9n8THjZQvXVWyf5Wn3T845KIRCBxPV_ZfGSYIMQ5wvQnD7zMmg</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Loo, Ronald K., MD</creator><creator>Lieberman, Stephen F., MD</creator><creator>Slezak, Jeff M., MS</creator><creator>Landa, Howard M., MD</creator><creator>Mariani, Albert J., MD</creator><creator>Nicolaisen, Gary, MD</creator><creator>Aspera, Ann M., MD</creator><creator>Jacobsen, Steven J., MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20130201</creationdate><title>Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria</title><author>Loo, Ronald K., MD ; Lieberman, Stephen F., MD ; Slezak, Jeff M., MS ; Landa, Howard M., MD ; Mariani, Albert J., MD ; Nicolaisen, Gary, MD ; Aspera, Ann M., MD ; Jacobsen, Steven J., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-3fabb9f545684c31bd9cb0a98f8f9a6144357df79f62c9c9c9f124707f79401c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asymptomatic Diseases - epidemiology</topic><topic>California - epidemiology</topic><topic>Causality</topic><topic>Cohort Studies</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Early Diagnosis</topic><topic>Female</topic><topic>Hematuria</topic><topic>Hematuria - diagnosis</topic><topic>Hematuria - epidemiology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Northwestern United States - epidemiology</topic><topic>Predictive Value of Tests</topic><topic>Prevention</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><topic>Sex Distribution</topic><topic>Sex Factors</topic><topic>United States</topic><topic>Unnecessary Procedures</topic><topic>Urinary tract cancer</topic><topic>Urologic Neoplasms - diagnosis</topic><topic>Urologic Neoplasms - epidemiology</topic><topic>Validation Studies as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loo, Ronald K., MD</creatorcontrib><creatorcontrib>Lieberman, Stephen F., MD</creatorcontrib><creatorcontrib>Slezak, Jeff M., MS</creatorcontrib><creatorcontrib>Landa, Howard M., MD</creatorcontrib><creatorcontrib>Mariani, Albert J., MD</creatorcontrib><creatorcontrib>Nicolaisen, Gary, MD</creatorcontrib><creatorcontrib>Aspera, Ann M., MD</creatorcontrib><creatorcontrib>Jacobsen, Steven J., MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loo, Ronald K., MD</au><au>Lieberman, Stephen F., MD</au><au>Slezak, Jeff M., MS</au><au>Landa, Howard M., MD</au><au>Mariani, Albert J., MD</au><au>Nicolaisen, Gary, MD</au><au>Aspera, Ann M., MD</au><au>Jacobsen, Steven J., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>88</volume><issue>2</issue><spage>129</spage><epage>138</epage><pages>129-138</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><coden>MACPAJ</coden><abstract>Abstract Objective To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. Patients and Methods We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptomatic microscopic hematuria during a 2-year period in an integrated care organization in 3 regions along the West Coast of the United States. A test cohort and validation cohort of patients with hematuria evaluations between January 9, 2009, and August 15, 2011, were identified. Patients were followed passively through their electronic health records for a diagnosis of urothelial or renal cancer. The degree of microscopic hematuria, history of gross hematuria, smoking history, age, race, imaging findings, and cystoscopy findings were evaluated as risk factors for malignant tumors. Results The test cohort consisted of 2630 patients, of whom 55 (2.1%) had a neoplasm detected and 50 (1.9%) had a pathologically confirmed urinary tract cancer. Age of 50 years or older and a recent diagnosis of gross hematuria were the strongest predictors of cancer. Male sex was also predictive of cancer, whereas smoking history and 25 or more red blood cells per high-power field on a recent urinalysis were not statistically significant. A Hematuria Risk Index developed from these factors had an area under the receiver operating characteristic curve of 0.809. In the validation cohort of 1784 patients, the Hematuria Risk Index performed comparably (area under the curve = 0.829). Overall, 32% of the population was identified as low risk and 0.2% had a cancer detected; 14% of the population was identified as high risk, of whom 11.1% had a cancer found. Conclusion These results suggest that a considerable proportion of patients could avoid extensive evaluations with the use of the Hematuria Risk Index.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>23312369</pmid><doi>10.1016/j.mayocp.2012.10.004</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-6196 |
ispartof | Mayo Clinic proceedings, 2013-02, Vol.88 (2), p.129-138 |
issn | 0025-6196 1942-5546 |
language | eng |
recordid | cdi_proquest_miscellaneous_1284286288 |
source | MEDLINE; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
subjects | Age Distribution Aged Aged, 80 and over Asymptomatic Diseases - epidemiology California - epidemiology Causality Cohort Studies Comorbidity Complications and side effects Early Diagnosis Female Hematuria Hematuria - diagnosis Hematuria - epidemiology Humans Internal Medicine Male Middle Aged Northwestern United States - epidemiology Predictive Value of Tests Prevention Prospective Studies Risk Factors ROC Curve Sex Distribution Sex Factors United States Unnecessary Procedures Urinary tract cancer Urologic Neoplasms - diagnosis Urologic Neoplasms - epidemiology Validation Studies as Topic |
title | Stratifying Risk of Urinary Tract Malignant Tumors in Patients With Asymptomatic Microscopic Hematuria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stratifying%20Risk%20of%20Urinary%20Tract%20Malignant%20Tumors%20in%20Patients%20With%20Asymptomatic%20Microscopic%20Hematuria&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Loo,%20Ronald%20K.,%20MD&rft.date=2013-02-01&rft.volume=88&rft.issue=2&rft.spage=129&rft.epage=138&rft.pages=129-138&rft.issn=0025-6196&rft.eissn=1942-5546&rft.coden=MACPAJ&rft_id=info:doi/10.1016/j.mayocp.2012.10.004&rft_dat=%3Cgale_proqu%3EA320735270%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1287929344&rft_id=info:pmid/23312369&rft_galeid=A320735270&rft_els_id=S0025619612009901&rfr_iscdi=true |